Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines
Open Access
- 1 September 2010
- journal article
- research article
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. 1 (Default) , 119-140
Abstract
Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we examined the effects of AZA and DAC in a panel of non-small cell lung cancer (NSCLC) cell lines. Of 5 NSCLC lines tested in a cell viability assay, all were sensitive to AZA (EC50 of 1.8–10.5 µM), while only H1299 cells were equally sensitive to DAC (EC50 of 5.1 µM). In the relatively DAC-insensitive cell line A549, both AZA and DAC caused DNA methyltransferase I depletion and DNA hypomethylation; however, only AZA significantly induced markers of DNA damage and apoptosis, suggesting that mechanisms in addition to, or other than, DNA hypomethylation are important for AZA-induced cell death. Cell cycle analysis indicated that AZA induced an accumulation of cells in sub-G1 phase, whereas DAC mainly caused an increase of cells in G2/M. Gene expression analysis of AZA- and DAC-treated cells revealed strikingly different profiles, with many genes distinctly regulated by each drug. In summary, while both AZA and DAC caused DNA hypomethylation, distinct effects were demonstrated on regulation of gene expression, cell cycle, DNA damage, and apoptosis.Keywords
This publication has 50 references indexed in Scilit:
- Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaCancer, 2007
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic SyndromesThe Journal of Clinical Pharmacology, 2005
- Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the icebergClinical Immunology, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survivalOncogene, 2001
- Cellular differentiation, cytidine analogs and DNA methylationCell, 1980
- Effects of 5-azacytidine on transfer RNA methyltransferases.1979
- INCORPORATION OF A POTENT ANTILEUKEMIC AGENT, 5-AZA-2'-DEOXYCYTIDINE, INTO DNA OF CELLS FROM LEUKEMIC MICE1977
- PHASE-2 STUDY OF 5-AZACYTIDINE IN SOLID TUMORS1977